Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Williams

Emergency Medicine San Antonio, TX Doctor of Osteopathy

NPI 1376582031 CMS profile 244357

8026 Floyd Curl, San Antonio, TX 78229

Open in the dashboard

General payments

$359,801

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,566 paid to institutions, not to them · program years 2021–2022

Through program year 2025, James Williams of San Antonio, TX is reported in the CMS Open Payments database as having received $359,801 across 330 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,566 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $265 3
2023 General $31,910 25
2022 General $191,173 158
2021 General $68,105 72
2020 General $21,915 19
2019 General $46,419 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Williams
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to James Williams were reported at $14. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year James Williams Emergency Medicine median Middle half National median
2019 $46,419 $51 $18–$128 $163
2020 $21,915 $29 $16–$99 $114
2021 $68,105 $40 $18–$124 $132
2022 $191,173 $49 $20–$134 $149
2023 $31,910 $51 $22–$142 $160
2024 $265 $52 $22–$150 $164
2025 $14 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $153,084 121 payments
  2. Janssen Pharmaceuticals, Inc $102,093 97 payments
  3. Alexion Pharmaceuticals, Inc. $69,966 62 payments
  4. Eagle Pharmaceuticals, Inc. $10,753 12 payments
  5. Portola Pharmaceuticals, Inc. $8,622 6 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $8,367 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $4,817 10 payments
  8. Instrumentation Laboratory Company $800 1 payment
  9. BTG International, Inc. $779 6 payments
  10. Quidel Corporation $200 1 payment
  11. Other $320 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $247,183 89 payments
  2. Travel and Lodging $58,962 114 payments
  3. Consulting Fee $38,769 18 payments
  4. Food and Beverage $7,388 105 payments
  5. Honoraria $5,000 3 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,500 1 payment
Products named General payments · program years 2019–2025
  1. ANDEXXA Rare Disease $163,644 121 payments
  2. XARELTO $102,112 98 payments
  3. Andexxa Hematology $40,448 46 payments
  4. LOKELMA $11,621 13 payments
  5. ANDEXXA Hematology/Neurology $8,622 6 payments
  6. PRADAXA $8,367 8 payments
  7. XIFAXAN $4,799 9 payments
  8. CROFAB $765 5 payments
  9. RELISTOR $170 3 payments
  10. PROCLAIM $120 1 payment
  11. Other $108 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$19,448

Medicare's payments for the services billed

Medicare patients

133

Average age 76

Services billed

146

78 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 51%
Ischemic heart disease 50%
Chronic kidney disease 46%
Depression 44%
Atrial fibrillation 40%
COPD 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record